One thing in the presentation was reference to current billion...

One thing in the presentation was reference to current billion dollar plus companies, already in the cancer drug marketplace. A bit unusual for the company to even hint,  in this fashion that KZA could also be in that league one day.

Anyway as I have suggested.....we can do better than one billion. The broker on their website say nett profit commence at $59m PA and peak at $139m PA in the last year of their Cantrixil patents 2035. So this possible $1b dollar market cap, comes not from an anonymous poster on the chatline, but rather from their own website.  

Few would be aware or probable even accept the fact, that these broker reports are commissioned by the company itself.  The latest two reports from late last year would (guess) cost $25,000. The broker would sit down with company representatives and basically assemble all the technical data. You can see the quality of these reports could only come from KZA itself. So there you have a document on their website of a much higher quality and content detail, than this latest presentation....and basically put together by the company itself. The management are ultra conservative, as discussed many time before. Why would the broker reports also not follow this approach ? Specific evidence has been presented here which strongly points to Cantrixil being effective the whole suite of solid cancers.  

-----

So the point is....its not really about clawing our way up to a $100m market cap, but maybe what the broker alludes to is a $1b cap.

This is the ballpark we are in, see below......all self explanatory here:

Key words in the story, that you have heard before : Cancer Stem Cells, Phase 1 Trial, Solid Cancers  

-------


https://www.*.com.au/stemcentrx-rova-t-data-2016-6?r=


June 6, 2016

"Until now, the second-largest acquisition in the history of venture capital was largely based on clinical trial data that hadn’t been released.

In April, Stemcentrx, a startup with backing from Silicon Valley investors including Artis Ventures and Founders Fund, was acquired by AbbVie for $5.8 billion in cash and stock in a deal that in total could be worth up to $10.2 billion. The deal officially closed June 1.

In data released Sunday at the American Society of Clinical Oncology conference, Stemcentrx showed that its drug could extend the lives of certain patients with small cell lung cancer. All of those patients had higher amounts of a specific protein.

Stemcentrx is researching drugs that are designed to treat cancer — specifically solid tumours — by targeting cancer stem cells. The intent is that by attacking those cells, it can stop the cancer from spreading. Unlike general adult stem cells, which are found all over the body as unspecified cells that can regenerate, cancer stem cells are a specific type of cancer cell that some research suggests could play a key role in defeating the disease.

The Stemcentrx drug that’s farthest along thus far is called rovalpitzumab tesirine, or Rova-T. It’s currently in trials to treat small-cell lung cancer, a type of lung cancer that makes up about 10% to 15% of all cases. The targeted drug goes after a special protein that may be linked to cancer stem cells. The protein, called DLL3, is highly expressed (meaning a genetic variation is telling the body to make a lot of it) in about 80% of tumours, Stemcentrx chief scientific officer Scott Dylla said on Friday at AbbVie’s research and development day based on data that he’s seen. Rova-T works by latching onto the protein, delivering the deadly toxin to the cell, and cutting off the tumour growth at its source.

The Phase 1 study released Sunday, which had the goal of showing that Rova-T is effective and safe to use, looked at 74 people with small cell lung cancer whose disease had gotten worse even with at least one other treatment option. Of the 60 who were able to be evaluated by the end of the trial, 11 saw tumour shrinkage. Those results started to look better when you look at the smaller group of 26 people with high levels of DLL3. Then, about 10 of those 26 responded to the treatment, and about 1/3 of those 26 people were alive after a year.

“Although these results are preliminary, rovalpituzumab tesirine seems to be the first targeted therapy to show efficacy in small cell lung cancer, and we may have identified DLL3 as the first predictive biomarker in this disease,” Dr. Charles Rudin, an oncologist at Memorial Sloan Kettering who led the study, said in a release. Rudin said later in a press briefing that the results should be taken with caution as it was still just a small group and the first study done in humans."